Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case.
Vallacchi V, Vergani E, Cossa M, Gargiuli C, Busico A, Devecchi A, Dugo M, Bergamaschi L, De Cecco L, Cavalieri S, Valeri B, Tamborini E, Gallino G, Del Vecchio M, Santinami M, Sensi M, Rivoltini L, Di Guardo L, Rodolfo M. Vallacchi V, et al. Among authors: rivoltini l. J Immunother Cancer. 2024 Jan 4;12(1):e007612. doi: 10.1136/jitc-2023-007612. J Immunother Cancer. 2024. PMID: 38177075 Free PMC article.
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.
Belli F, Arienti F, Rivoltini L, Santinami M, Mascheroni L, Prada A, Ammatuna M, Marchesi E, Parmiani G, Cascinelli N, et al. Belli F, et al. Among authors: rivoltini l. Melanoma Res. 1992 Nov;2(4):263-71. doi: 10.1097/00008390-199211000-00007. Melanoma Res. 1992. PMID: 1490114
Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wölfel T, et al. Sensi M, et al. Among authors: rivoltini l. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5674-8. doi: 10.1073/pnas.92.12.5674. Proc Natl Acad Sci U S A. 1995. PMID: 7777568 Free PMC article.
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2.
Arienti F, Belli F, Rivoltini L, Gambacorti-Passerini C, Furlan L, Mascheroni L, Prada A, Rizzi M, Marchesi E, Vaglini M, et al. Arienti F, et al. Among authors: rivoltini l. Cancer Immunol Immunother. 1993 May;36(5):315-22. doi: 10.1007/BF01741170. Cancer Immunol Immunother. 1993. PMID: 8477417 Free PMC article.
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells.
Arienti F, Belli F, Napolitano F, Sulé-Suso J, Mazzocchi A, Gallino GF, Cattelan A, Santantonio C, Rivoltini L, Melani C, Colombo MP, Cascinelli N, Maio M, Parmiani G. Arienti F, et al. Among authors: rivoltini l. Hum Gene Ther. 1999 Dec 10;10(18):2907-16. doi: 10.1089/10430349950016320. Hum Gene Ther. 1999. PMID: 10609652 Clinical Trial.
Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes.
Mazzocchi A, Melani C, Rivoltini L, Castelli C, Del Vecchio M, Lombardo C, Colombo MP, Parmiani G. Mazzocchi A, et al. Among authors: rivoltini l. Cancer Immunol Immunother. 2001 Jun;50(4):199-211. doi: 10.1007/pl00006687. Cancer Immunol Immunother. 2001. PMID: 11459172 Free PMC article.
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchianò A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G. Belli F, et al. Among authors: rivoltini l. J Clin Oncol. 2002 Oct 15;20(20):4169-80. doi: 10.1200/JCO.2002.09.134. J Clin Oncol. 2002. PMID: 12377960 Clinical Trial.
234 results